Systemic lupus erythematosus (SLE) is the form of the disease that most people are referring to when they say "lupus." The word "systemic" means the disease can affect many parts of the body. The symptoms of SLE may be mild or serious. Although SLE usually first affects people between the ages of 15 and 45 years, it can occur in childhood or later in life as well.
A team of researchers from Charité - Universitätsmedizin Berlin and the Deutsches Rheuma-Forschungszentrum Berlin, a Leibniz Institute, have successfully treated two patients with the autoimmune disease systemic lupus erythematosus.
Now a new study by researchers at SUNY Upstate Medical University and published recently on the preprint server medRxiv in September 2020 shows that memory B cells are upregulated in convalescent COVID-19 patients, correlating with a better immune response and shorter symptom duration.
Researchers at Case Western Reserve University have added to the growing body of understanding about how hydroxychloroquine (HCQ) is not a possible defense against COVID-19.
A team of researchers from Children's Hospital of Philadelphia (CHOP) used a new method of pinpointing potential disease-causing changes in the genome to identify two new potential therapeutic targets for lupus, while also paving the way for more accurately identifying disease-causing variations in other autoimmune disorders.
The ongoing COVID-19 pandemic has cost hundreds of thousands of human lives, besides more than 11 million cases. Caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the disease was initially thought to be more severe in the elderly and those with pre-existing medical conditions. However, it started to manifest in children after the peak of the first wave.
A new study published on the preprint server medRxiv in June 2020 shows that the drug hydroxychloroquine (HCQ) suppresses a form of immunity called ‘trained immunity,’ with repercussions for its potential use to treat COVID-19.
Researchers at Uppsala University and Uppsala University Hospital have developed a new method to measure levels of the medication hydroxychloroquine in patients with rheumatic disease systemic lupus erythematosus (SLE).
A new study by investigators from Brigham and Women's Hospital examines changes in prescription patterns in the United States during the COVID-19 pandemic.
Variants in a gene of the human immune system cause men and women to have different vulnerabilities to the autoimmune diseases lupus and Sjögren's syndrome, according to findings published in the journal Nature.
Some diseases exhibit a clear sex bias, occurring more often, hitting harder or eliciting different symptoms in men or women.
Over the past few months, doctors resorted to repurposing medicines that have already been approved for other diseases to treat coronavirus patients. One drug that was widely used in the pandemic, hydroxychloroquine, has been found to be ineffective in treating the viral infection.
Working alongside colleagues in Mainz, Bern, Hannover and Bonn, researchers from Charité - Universitätsmedizin Berlin, the Berlin Institute of Health and the German Rheumatism Research Center Berlin were able to show how the microbiome helps to render the immune system capable of responding to pathogens.
University of Houston Hugh Roy and Lillie Cranz Cullen Endowed Professor of biomedical engineering, Chandra Mohan, and his team have discovered a difference in urinary biomarker proteins of lupus nephritis in patients according to race.
The disease course of COVID-19 is diverse, ranging from asymptomatic to fatal respiratory failure. Scientists have been working to uncover the immunological reasons behind this heterogeneity. A recent study on B cells, published on the preprint server medRxiv in April 2020, shows that extrafollicular B cells could be a marker of severe infection in the early stages, predicting the need for earlier immunomodulatory therapy.
The spread of the pandemic disease COVID-19 caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has now reached almost every country of the world, with over 3.11 million cases and over 217,000 deaths as of April 29, 2020.
A new review paper published in the preprint open-access journal medRxiv in April 2020 reports that there is not enough evidence to justify the widespread use of the drug hydroxychloroquine (HCQ) in the treatment or prophylaxis of the current COVID-19 illness.
Following the emergence of a novel coronavirus in Wuhan, China, in the last month of 2019, it has spread globally to produce the first pandemic of the 21st century. The virus, called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has already affected over 2.5 million and killed more than 177,000 people as of April 22, 2020.
Like a parent of teenagers at a party, Mother Nature depends on chaperones to keep one of her charges, the immune system, in line so that it doesn't mistakenly attack normal cells, tissues and organs in our bodies.
A drug used for cancer therapy has shown promise in reversing kidney damage caused by systemic lupus erythematosus.
Researchers provide a guideline regarding who should be actually taking antimalarial drugs as prophylaxis to prevent getting COVID-19. They say health professionals who are being exposed to COVID-19 positive patients and those who test positive but are asymptomatic should be taking drugs such as Chloroquine and Hydroxychloroquine. They explain that these populations remain most in need, and because of limited supply, these individuals need to be prioritized.